RAD 001 (Everolimus) Prevents mTOR and Akt Late Re-Activation in Response to Imatinib in Chronic Myeloid Leukemia

The mammalian target of rapamycin (mTOR) is one target of BCR-ABL fusion gene of chronic myeloid leukemia (CML). Moreover, it drives a compensatory route to Imatinib mesylate (IM) possibly involved in the progression of leukemic progenitors towards a drug-resistant phenotype. Accordingly, mTOR inhibitors are proposed for combined therapeutic strategies in CIVIL. The major caveat in the use of mTOR inhibitors for cancer therapy comes front the induction of an mTOR-phosphatidylinositol 3 kinase (PI3k) feedback loop driving file retrograde activation of Akt. Here we show that the rapamycin derivative RAD 001 (everolimus, Novartis Institutes for Biomedical Research) inhibits mTOR and, more importantly, revokes mTOR late re-activation in response to IM. RAID 001 interferes with the assembly of both mTOR complexes: mTORC1 and mTORC2. The inhibition of mTORC2 results in the de-phosphorylation of Akt at Set 47 3 in the hydrophobic motif of C-terminal tail required For Akt full activation and precludes Akt re-phosphorylation in response to IM. Moreover, RAD 001-induced inhibition of Akt Causes the de-phosphorylation of tuberous sclerosis junior Suppressor protein TSC2 at 14-3-3 binding sites, TSC2 release front 14-3-3 sigma (restoring its inhibitory function on mTORC1) and nuclear import (promoting the nuclear translocation of cyclin-dependent kinase [CDK] inhibitor p27(Kip1), the stabilization of p27(Kip1) ligand with CDK2, and the G(0)/G(1), arrest). RAD 001 cytotoxicity on cells not expressing the BCR-ABL fusion gene of its p210 protein tyrosine kinase (TK) activity suggests that the inhibition of normal hematopoiesis may represent a drug side effect. J. Cell. Biochem. 109: 320-328, 2010. (C) 2009 Wiley-Liss, Inc.